Artificial intelligence is already proving it can accelerate drug development and improve our understanding of disease. But to turn AI into novel treatments we need to get the latest, most powerful models into the hands of scientists. The problem is that most scientists aren't machine-learning experts. Now the company OpenProtein.AI is helping scientists stay on the cutting edge of AI with a no-code platform that gives them access to powerful foundation models and a suite of tools for designing proteins, predicting protein structure and function, and training models. The company, founded by Tristan Bepler PhD '20 and former MIT associate professor Tim Lu PhD '07, is already equipping researchers in pharmaceutical and biotech companies of all sizes with its tools, including internally developed foundation models for protein engineering. OpenProtein.AI also offers its platform to scientists in academia for free. 'It's a really exciting time right now because these models can not only...
learn more
